Literature DB >> 6609266

Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.

M Rosenstein, S A Rosenberg.   

Abstract

T-cell clones that exhibited both lytic and proliferative activity for the syngeneic FBL-3 lymphoma were isolated from in vitro sensitization cultures. These clones were Lyt-2+ and proliferated specifically to the FBL-3 lymphoma but not to other tumors of C57BL/6 origin, allogeneic tumor, or C57BL/6 normal lymphocytes. Adoptive transfer of clones exhibiting both proliferative and cytotoxic activity prolonged survival and occasionally cured the animals of disseminated FBL-3 lymphomas, while T-cell clones exhibiting lytic but no proliferative activity conferred no survival benefit compared to the survival seen among animals receiving no treatment.

Entities:  

Mesh：

Year:  1984        PMID： 6609266

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


  12 in total

1.  The effect of cimetidine on PBL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production.

Authors:  A Eisenthal; J Monselise; R Zinger; A Adler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.

Authors:  R L Kradin; L A Boyle; F I Preffer; R J Callahan; M Barlai-Kovach; H W Strauss; S Dubinett; J T Kurnick
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells.

Authors:  A Aruga; S Shu; A E Chang
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

Review 4.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

5.  The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues.

Authors:  E A Grimm; B M Vose; E W Chu; D J Wilson; M T Lotze; A A Rayner; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid.

Authors:  A Belldegrun; A Kasid; M Uppenkamp; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.

Authors:  M A Cheever; D B Thompson; J P Klarnet; P D Greenberg
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

8.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Authors:  R J Barth; J J Mulé; P J Spiess; S A Rosenberg
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

9.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

Authors:  P D Greenberg; D E Kern; M A Cheever
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.

Authors:  K Sakamoto; T Yoshioka; J Shimizu; S Sato; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1988-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.